Jiang J L, van Rhee A M, Melman N, Ji X D, Jacobson K A
Molecular Recognition Section, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA.
J Med Chem. 1996 Nov 8;39(23):4667-75. doi: 10.1021/jm960457c.
An approach to designing dihydropyridines that bind to adenosine receptors without binding to L-type calcium channels has been described. 1,4-Dihydropyridine derivatives substituted with beta-styryl or phenylethynyl groups at the 4-position and aryl groups at the 6-position were synthesized and found to be selective for human A3 receptors. Combinations of methyl, ethyl, and benzyl esters were included at the 3- and 5-positions. Affinity was determined in radioligand binding assays at rat brain A1 and A2A receptors using [3H]-(R)-PIA [[3H]-(R)-N6-(phenylisopropyl)adenosine] and [3H]CGS 21680 [[3H]-2-[[4-(2-carboxyethyl)phenyl]ethylamino]-5'- (N-ethylcarbamoyl)adenosine], respectively. Affinity was determined at cloned human and rat A3 receptors using [125I]AB-MECA [N6-(4-amino-3-iodobenzyl)-5'-(N-ethylcarbamoyl)-adenosine]. Structure-activity analysis indicated that substitution of the phenyl ring of the beta-styryl group but not of the 6-phenyl substituent was tolerated in A3 receptor selective agents. Replacement of the 6-phenyl ring with a 3-thienyl or 3-furyl group reduced the affinity at A3 receptors by 4- and 9-fold, respectively. A 5-benzyl ester 4-trans-beta-styryl derivative, 26, with a Ki value of 58.3 nM at A3 receptors, was > 1700-fold selective vs either A1 receptors or A2A receptors. Shifting the benzyl ester to the 3-position lowered the affinity at A3 receptors 3-fold. A 5-benzyl, 3-ethyl ester 4-phenylethynyl derivative, 28, displayed a Ki value of 31.4 nM at A3 receptors and 1300-fold selectivity vs A1 receptors. The isomeric 3-benzyl, 5-ethyl diester was > 600-fold selective for A3 receptors. Oxidation of 28 to the corresponding pyridine derivative reduced affinity at A3 receptors by 88-fold and slightly increased affinity at A1 receptors.
已经描述了一种设计二氢吡啶的方法,该二氢吡啶可与腺苷受体结合而不与L型钙通道结合。合成了在4位被β-苯乙烯基或苯乙炔基取代且在6位被芳基取代的1,4 - 二氢吡啶衍生物,发现它们对人A3受体具有选择性。在3位和5位包含了甲酯、乙酯和苄酯的组合。分别使用[3H]-(R)-PIA [[3H]-(R)-N6-(苯异丙基)腺苷]和[3H]CGS 21680 [[3H]-2-[[4-(2 - 羧乙基)苯基]乙氨基]-5'-(N - 乙基氨基甲酰基)腺苷]通过放射性配体结合试验测定大鼠脑A1和A2A受体的亲和力。使用[125I]AB - MECA [N6-(4 - 氨基 - 3 - 碘苄基)-5'-(N - 乙基氨基甲酰基)-腺苷]测定克隆的人和大鼠A3受体的亲和力。构效分析表明,在A3受体选择性药物中,β-苯乙烯基的苯环取代是可以接受的,但6 - 苯基取代基的取代则不行。用3 - 噻吩基或3 - 呋喃基取代6 - 苯环分别使A3受体的亲和力降低了4倍和9倍。一种5 - 苄酯4 - 反式 - β - 苯乙烯基衍生物26,在A3受体处的Ki值为58.3 nM,对A1受体或A2A受体的选择性大于1700倍。将苄酯移至3位会使A3受体的亲和力降低3倍。一种5 - 苄基、3 - 乙酯4 - 苯乙炔基衍生物28,在A3受体处的Ki值为31.4 nM,对A1受体的选择性为1300倍。异构体3 - 苄基、5 - 乙酯对A3受体的选择性大于600倍。将28氧化为相应的吡啶衍生物会使A3受体的亲和力降低88倍,并使A1受体的亲和力略有增加。